Compare UCTT & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UCTT | STOK |
|---|---|---|
| Founded | 1991 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.0B |
| IPO Year | 2004 | 2019 |
| Metric | UCTT | STOK |
|---|---|---|
| Price | $59.46 | $35.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $75.00 | $36.10 |
| AVG Volume (30 Days) | ★ 1.2M | 566.7K |
| Earning Date | 01-01-0001 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 30.67 |
| EPS | N/A | ★ 0.85 |
| Revenue | ★ $1,734,500,000.00 | $36,555,000.00 |
| Revenue This Year | $8.52 | $430.19 |
| Revenue Next Year | $15.30 | N/A |
| P/E Ratio | ★ N/A | $41.76 |
| Revenue Growth | N/A | ★ 316.34 |
| 52 Week Low | $16.66 | $5.35 |
| 52 Week High | $73.80 | $38.62 |
| Indicator | UCTT | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 59.13 | 63.53 |
| Support Level | $22.71 | $30.50 |
| Resistance Level | N/A | $37.98 |
| Average True Range (ATR) | 4.71 | 2.05 |
| MACD | 0.61 | 0.44 |
| Stochastic Oscillator | 49.86 | 72.82 |
Ultra Clean Holdings Inc, through its subsidiaries, manufactures and supplies production tools, modules, and subsystems for the semiconductor capital equipment industry. The product includes precision robotic solutions, gas delivery systems, and a variety of industrial and automation production equipment products; subsystems include wafer cleaning subsystems, chemical delivery modules, top-plate assemblies, frame assemblies, and process modules. Its customer base includes firms in the semiconductor capital equipment industry, medical, energy, industrial, flat panel, and research equipment industries. It has two segments Products and Services. Its principal markets are Americas, Asia Pacific and EMEA.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.